How Amgen & HealthVerity found treatment gaps in high-risk diabetes care
Amgen’s new retrospective study, VESALIUS-REAL, examines how lipid-lowering therapy (LLT) is being...
Amgen’s new retrospective study, VESALIUS-REAL, examines how lipid-lowering therapy (LLT) is being...
Antiretroviral therapy (ART) has transformed outcomes for people living with HIV, especially those...
Government health agencies are increasingly turning to real-world data (RWD) for public health...
A new peer-reviewed study from the Centers for Disease Control and Prevention (CDC) highlights the...
Background While the COVID-19 pandemic is behind us, the virus remains a concern that needs to be...
The COVID-19 pandemic illustrated how vital government communications can be for effective public...
Medicaid provides much-needed healthcare coverage to over 70 million people, almost half of whom...
While the CDC is considered the nation’s leading authority on infectious diseases, it is also...
Our series on how Privacy Preserving Record Linkage (PPRL) technology can help government agencies...
In our ongoing series on how Privacy-Preserving Record Linkage (PPRL) technology can help...
Amgen’s new retrospective study, VESALIUS-REAL, examines how lipid-lowering therapy (LLT) is being used in clinical practice for patients with high-risk diabetes.1 The study draws on Verified de-identified medical and pharmacy claims from 2016 to 202...